Pressure BioSciences, Inc. (Nasdaq:PBIO) (“PBI” and “the Company”) today announced that two leading biotechnology publications with worldwide readership and importance have highlighted the Company’s powerful and enabling pressure cycling technology (“PCT”) platform in their just released August issues. The publications are Genetic Engineering & Biotechnology News (“GEN”) and Expert Review of Proteomics (“ERP”). Both publications highlighted the May 2010 Symposium on the Applications of Ultra-high Pressure in Biotechnology held at Harvard Medical School. The Symposium featured presentations on the advantages of PCT from a prestigious group of fourteen scientists from North America.
About Genetic Engineering & Biotechnology News (“GEN”). GEN has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN’s unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization. Here is the Link to the story: http://www.genengnews.com/gen-articles/use-of-ultrahigh-pressure-on-the -ise/3360/.
About Expert Review of Proteomics (“ERP”). Modern research is revealing protein sequences that hold the key to understanding human biological processes. However, many obstacles face the R&D community in determining protein structure, function and expression. ERP addresses the key technologies and methods that promise to advance our understanding of the many varied roles protein expression plays in health and disease. Here is the Link to the journal supplement: http://www.expert-reviews.com/toc/epr/7/4s.
R. Wayne Fritzsche, Chairman of the Board of PBI, said: “We believe the focus that GEN and ERP have given PCT in their August issues further validates this very enabling and powerful sample preparation platform. We further believe these publications will be seen by scientists around the world, many of whom have existing needs that PCT can fulfil, but who have not yet learned about the capabilities of PBI’s pressure cycling technology. Lastly, we believe that this added, widespread exposure and validation will result in additional sales of our PCT Sample Preparation Systems in the near future.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development and sale of instruments and consumables based on a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 14 US and 10 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical and enzymatic reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts in the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications.
Forward Looking Statements
Statements contained in this press release regarding PBI’s intentions, hopes, beliefs, expectations, or predictions of the future are “forward-looking’’ statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements include statements regarding the widespread readership and important roles of GEN and ERP; the validation that the publication of the Harvard Symposium in GEN and ERP has engendered; the number of readers that will see the GEN and ERP publications worldwide; the advantages of PCT in sample preparation; and that exposure from the GEN and ERP publications will result in an increase in sales. These statements are based upon PBI’s current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties, delays and additional costs in the implementation of PBI’s strategies that may adversely affect the commercialization of PCT and PCT-dependent products; PBI’s sales force may not successfully sell the PCT product line because scientists may not perceive the advantages of PCT for their sample preparation needs; scientists may be unable to duplicate the results achieved using PCT reported at the May 2010 Symposium on the Applications of Ultra-high Pressure in Biotechnology, and consequently the GEN and ERP publications regarding the Symposium presentations may not lead to an increase in sales of the PCT Sample Preparation System. Further, the Company expects that it will need additional capital to fund its continuing operations beyond the first quarter of 2011. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading “Risk Factors” in PBI’s Annual Report on Form 10-K for the year ended December 31, 2009, and other reports filed by PBI from time to time with the SEC. PBI undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
Visit us at our website http://www.pressurebiosciences.com
CONTACT: Pressure BioSciences, Inc. Investor Contacts: Richard T. Schumacher, President and CEO R. Wayne Fritzsche, Chairman (508) 230-1828
